BCM
EGRX

Beck Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Beck Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,495
Closed -$525K – 148
2015
Q2 		$525K Buy
+6,495
New +$423K 0.28% 79

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
GE
General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

Beck Capital Management's EGRX Position: Q3 2015 in Review

Beck Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2015, closing a stake of 6,495 shares — an estimated $525K sold.

Beck Capital Management first reported a position in EGRX in Q2 2015 and held it in 1 quarter. The position peaked at $525K in Q2 2015. 119 funds tracked by Wall St. Rank hold EGRX as of Q3 2015.

  • Beck Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Beck Capital Management sold 6,495 Eagle Pharmaceuticals, Inc. shares in Q3 2015, an estimated $525K.
  • Beck Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Beck Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $525K in Q2 2015.
  • 119 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2015.

Based on Beck Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.